Surrozen, Inc. (NASDAQ:SRZN) Sees Large Increase in Short Interest

Surrozen, Inc. (NASDAQ:SRZN) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 45,400 shares, a growth of 33.9% from the November 30th total of 33,900 shares. Currently, 1.9% of the company’s stock are short sold. Based on an average daily trading volume, of 33,200 shares, the days-to-cover ratio is presently 1.4 days.

Hedge Funds Weigh In On Surrozen

Several institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC raised its position in Surrozen by 66.5% during the 3rd quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock worth $1,318,000 after buying an additional 43,916 shares during the last quarter. CVI Holdings LLC purchased a new position in Surrozen during the second quarter worth about $711,000. Nantahala Capital Management LLC acquired a new stake in Surrozen in the second quarter valued at about $2,050,000. Finally, Armistice Capital LLC acquired a new stake in Surrozen in the second quarter valued at about $2,080,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Trading Down 6.0 %

Shares of SRZN traded down $0.88 during mid-day trading on Friday, reaching $13.90. The company’s stock had a trading volume of 48,850 shares, compared to its average volume of 18,479. Surrozen has a 12-month low of $6.00 and a 12-month high of $16.19. The company’s 50 day moving average is $10.44 and its 200 day moving average is $9.76.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($2.77) by $2.33. The firm had revenue of $10.00 million for the quarter. As a group, equities research analysts expect that Surrozen will post -7.16 EPS for the current fiscal year.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.